Cargando…
Pushing forward in sarcoma with a new TCR targeting NY-ESO-1
A phase 1 trial demonstrating the safety and efficacy of a novel NY-ESO-1-specific TCR-T cells by Pan et al.(1) is a major step forward for adoptive T cell therapy in the clinical practice of advanced soft tissue sarcomas.
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439265/ https://www.ncbi.nlm.nih.gov/pubmed/37586326 http://dx.doi.org/10.1016/j.xcrm.2023.101159 |